BEGIN:VCALENDAR VERSION:2.0 PRODID:-//wp-events-plugin.com//7.4.3//EN TZID:Europe/Rome X-WR-TIMEZONE:Europe/Rome BEGIN:VEVENT UID:45@fasieventi.com DTSTART;TZID=Europe/Rome;VALUE=DATE:20230908 DTEND;TZID=Europe/Rome;VALUE=DATE:20230910 DTSTAMP:20240625T120518Z URL:https://www.fasieventi.com/events/up-to-date-on-thyroid-eye-disease-no vel-insights-and-treatment/ SUMMARY:UP TO DATE ON Thyroid eye disease NOVEL INSIGHTS AND TREATMENT DESCRIPTION:SEDE: Aula Granelli\nPadiglione Granelli-Marcora\nPoliclinico\, Ospedale Maggiore\nVia Francesco Sforza 35 - Milano\n \;\nFRIDAY\, SE PTEMBER 8TH\n \;\n\n2.00 pm / Welcoming address and presentation of t he Symposium\n \;\nThe role of microbiota in Graves’ disease and ass ociated orbitopathy\n2.30 pm / Experimental evidence from a mouse model of TED - Giulia Masetti (IT)\n2.50 pm / Evidence in humans - Marian Ludgate (UK)\n \;\nBlockade of the IGF-1 receptor: studies with linsitinib\n3. 10 pm / Linsitinib treatment in a mouse model of TED - Anja Eckstein (DE)\ n3.30 pm / The VGN-TED 301 trial: an update - Raymond Douglas (US)\n \ ;\n3.50 pm / Coffee break\n \;\nAnti-TSHr blockade and novel immunosup pressants in active TED\n4.20 pm / K1-70 targeting of the TSH receptor - Jane Sanders (UK)\n4.40 pm / Belimumab (anti-BAFF) in active TED - Irene C ampi (IT)\n4.55 pm / Rationale and efficacy of Sirolimus treatment in TED - Michele Marinò (IT)\n \;\nOngoing Randomized Controlled Trials in T ED\n5.10 pm / The IMVT-1401-3201/3203 trials: rationale - Marius Stan (US) \n5.30 pm / Tocilizumab in active TED: the Italian multicenter trial - Ila ria Muller (IT)\n5.50 pm / The VRDN - 001 clinical trial: an update - Raym ond Douglas (US)\n \;\n6.10 pm / Discussion and conclusion\n\n\n \ ;\n\n\nSATURDAY\, SEPTEMBER 9TH\n \;\n\n\n8.50 am / Reconvening of the Symposium\n \;\nExperience with Teprotumumab in a US Multidisciplinar y TED clinic\n9.00 am / Introduction of Teprotumumab &\; Endocrine Cons iderations\nChrysoula Dosiou (US)\n9.20 am / Ophthalmic Considerations for Teprotumumab Therapy\nAndrea Kossler (US)\n9.40 am / The safety profile o f Teprotumumab - Marius Stan (US)\n \;\nAssessment of treatment outcom es in TED: are the tools of the trade fit for purpose?\n10.00 am / Outcom es of efficacy: inflammation\, proptosis or both? - Luigi Bartalena (IT)\, Marius Stan (US)\, Petros Perros (UK)\n \;\n10.40 am / Coffee break\n  \;\nUpdate on the surgical treatment of TED\n11.00 am / Endoscopic or bital surgery for dysthyroid optic neuropathy - Claudio Guastella (IT)\n11 .20 am / Ophthalmological/surgical integrated management of dysthyroid opt ic neuropathy - Nicola Currò (IT)\n11.35 am / Neuronavigation in orbital surgery - Lelio Baldeschi (IT)\n \;\nRound table Prevention of TED\n11 .50 am / Preventable risk factors - Maria Laura Tanda (IT)\n12.00 pm / The TEARS proposal - Lelio Baldeschi (IT)\, Anja Eckstein (DE)\, Petros Perro s (UK)\n12.20 pm / The Milan Pledge - Mario Salvi (IT)\n \;\n12.30 pm / Concluding remarks\n ATTACH;FMTTYPE=image/jpeg:https://www.fasieventi.com/wp-content/uploads/20 23/09/thyroid-eye-disease_settembre2023.jpg LOCATION:Policlinico di Milano Ospedale Maggiore\, Via Francesco Sforza\, 3 5\, Milano \, MI\, 20122 \, Lombardia\, Italia X-APPLE-STRUCTURED-LOCATION;VALUE=URI;X-ADDRESS=Via Francesco Sforza\, 35\, Milano \, MI\, 20122 \, Lombardia\, Italia;X-APPLE-RADIUS=100;X-TITLE=Pol iclinico di Milano Ospedale Maggiore:geo:0,0 END:VEVENT BEGIN:VTIMEZONE TZID:Europe/Rome X-LIC-LOCATION:Europe/Rome BEGIN:DAYLIGHT DTSTART:20230326T030000 TZOFFSETFROM:+0100 TZOFFSETTO:+0200 TZNAME:CEST END:DAYLIGHT END:VTIMEZONE END:VCALENDAR